

Joe Hirman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12061281/publications.pdf>

Version: 2024-02-01

27
papers

2,053
citations

567281

15
h-index

526287

27
g-index

27
all docs

27
docs citations

27
times ranked

1694
citing authors

#	ARTICLE	IF	CITATIONS
1	A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients With Sepsis and Suspected Disseminated Intravascular Coagulation*. <i>Critical Care Medicine</i> , 2013, 41, 2069-2079.	0.9	423
2	Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. <i>Lancet Neurology</i> , The, 2014, 13, 1100-1107.	10.2	333
3	Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. <i>Lancet Neurology</i> , The, 2014, 13, 676-685.	10.2	245
4	Efficacy and safety of eptinezumab in patients with chronic migraine. <i>Neurology</i> , 2020, 94, e1365-e1377.	1.1	236
5	Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1). <i>Cephalalgia</i> , 2020, 40, 241-254.	3.9	230
6	Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial. <i>Cephalalgia</i> , 2019, 39, 1075-1085.	3.9	107
7	A Double-Blind, Placebo-Controlled, Ascending-Dose, Randomized Study to Evaluate the Safety, Tolerability and Effects on Cognition of AL-108 after 12 Weeks of Intranasal Administration in Subjects with Mild Cognitive Impairment. <i>Dementia and Geriatric Cognitive Disorders</i> , 2013, 35, 325-339.	1.5	93
8	Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and) <i>Tj ETQq0 0 0 rgBv, Overlock 10 Tf 50 4</i>		
9	Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: Subgroup analysis of PROMISE-2. <i>Headache</i> , 2021, 61, 125-136.	3.9	55
10	Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial. <i>BMC Neurology</i> , 2021, 21, 126.	1.8	43
11	Eptinezumab for the Prevention of Episodic Migraine: Sustained Effect Through 1 Year of Treatment in the PROMISE-1 Study. <i>Clinical Therapeutics</i> , 2020, 42, 2254-2265.e3.	2.5	35
12	Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing. <i>Headache</i> , 2020, 60, 2220-2231.	3.9	34
13	Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials. <i>Journal of Headache and Pain</i> , 2021, 22, 16.	6.0	23
14	Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication-overuse headache. <i>Headache</i> , 2021, 61, 1421-1431.	3.9	22
15	Patient-identified most bothersome symptom in preventive migraine treatment with eptinezumab: A novel patient-centered outcome. <i>Headache</i> , 2021, 61, 766-776.	3.9	20
16	Dysregulation of Inflammatory and Hemostatic Markers in Sepsis and Suspected Disseminated Intravascular Coagulation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2015, 21, 120-127.	1.7	19
17	Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: Post hoc analysis of PROMISE-1 and PROMISE-2. <i>Cephalalgia</i> , 2022, 42, 696-704.	3.9	11
18	Impact of Baseline Characteristics on the Efficacy and Safety of Eptinezumab in Patients With Migraine: Subgroup Analyses of PROMISE-1 and PROMISE-2. <i>Clinical Therapeutics</i> , 2022, 44, 389-402.	2.5	10

#	ARTICLE	IF	CITATIONS
19	Early response to eptinezumab indicates high likelihood of continued response in patients with chronic migraine. <i>Journal of Headache and Pain</i> , 2022, 23, 29.	6.0	9
20	Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations. <i>Parkinsonism and Related Disorders</i> , 2019, 60, 138-145.	2.2	7
21	Tolerability of eptinezumab in overweight, obese or type 1 diabetes patients. <i>Endocrinology, Diabetes and Metabolism</i> , 2021, 4, e00217.	2.4	6
22	Cardiovascular outcomes in adults with migraine treated with eptinezumab for migraine prevention: pooled data from four randomized, double-blind, placebo-controlled studies. <i>Journal of Headache and Pain</i> , 2021, 22, 143.	6.0	6
23	Eptinezumab for migraine prevention in patients 50 years or older. <i>Acta Neurologica Scandinavica</i> , 2022, 145, 698-705.	2.1	6
24	Measuring dose-related efficacy of eptinezumab for migraine prevention: post hoc analysis of PROMISE-1 and PROMISE-2. <i>Journal of Headache and Pain</i> , 2022, 23, 48.	6.0	6
25	Long-term reductions in disease impact in patients with chronic migraine following preventive treatment with eptinezumab. <i>BMC Neurology</i> , 2022, 22, .	1.8	5
26	Patient-reported outcomes, health-related quality of life, and acute medication use in patients with ≥75% response to eptinezumab: subgroup pooled analysis of the PROMISE trials. <i>Journal of Headache and Pain</i> , 2022, 23, 23.		4
27	Likelihood of response with subsequent dosing for patients with migraine and initial suboptimal response with eptinezumab: A post hoc analysis of two placebo-controlled randomized clinical trials. <i>Headache</i> , 2022, 62, 558-565.	3.9	4